Pharma BD Deal Intelligence

Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd.

2005 · Acquisition/Merger · Complete

CALLED IT — OFF BY 4

The 2005 Yamanouchi-Fujisawa merger of equals created Astellas Pharma, which 21 years later is a top-20 global pharma with record ¥2.1T+ revenue, powered by oncology blockbusters built on the combined legacy franchises.

Full analysis, sources & comparables →

The coverage arc

Apr 01, 2005 Astellas Pharma — "A New Star in the World Pharmaceutical Industry" (formation announcement) Bullish

Astellas's formation announcement framed the new entity as 'A New Star in the World Pharmaceutical Industry' anchored on Prograf, Harnal/Flomax, and Vesicare,…

Jan 01, 2012 Yakugaku Zasshi / PMC (peer-reviewed strategy commentary) Bullish

Post-merger, Astellas explicitly pivoted toward oncology, declaring 'oncology' a strategic focus and pursuing the OSI Pharmaceuticals acquisition for Tarceva…

Jan 01, 2014 Companies History Bullish

Astellas Pharma 'was established through a merger of equals on April 1, 2005,' combining Fujisawa's Prograf-anchored transplant franchise with Yamanouchi's…

Source summaries from our enrichment pipeline; follow links for originals.

All 5 sources with sentiment breakdown →

The merger of equals between Yamanouchi and Fujisawa completed effective April 1, 2005, forming Astellas Pharma Inc., then Japan's #2 pharmaceutical company, via a stock-for-stock share exchange with Yamanouchi as the legal surviving entity and no cash consideration. The combination united Fujisawa's Prograf transplant franchise with Yamanouchi's Harnal urology franchise on combined 2004 predecessor revenues of roughly $7.9 billion.

Did it work? Outcome assessment

The 2005 Yamanouchi-Fujisawa merger of equals created Astellas Pharma, which 21 years later is a top-20 global pharma with record ¥2.1T+ revenue, powered by oncology blockbusters built on the combined legacy franchises.

Strategic verdict
Achieved Stated Rationale

Key facts

Related deals — scored

DealYearValueOutcome
Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. (this deal)200592
Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd.2004$7.6B84
AstraZeneca PLC / KuDOS Pharmaceuticals Limited2005$210M98
Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd.2005$8.0B92
Cephalon Inc. / Salmedix, Inc.2005$160M89
Roche Holding AG / GlycArt Biotechnology AG2005$182M80
Reckitt Benckiser plc / Boots Healthcare International2005$3.4B78

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →